Article(id=1330225643272384636, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225632362999820, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2022.06.002, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1638288000000, receivedDateStr=2021-12-01, revisedDate=1649692800000, revisedDateStr=2022-04-12, acceptedDate=null, acceptedDateStr=null, onlineDate=1795080107753, onlineDateStr=2026-11-19, pubDate=1654790400000, pubDateStr=2022-06-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795080107753, onlineIssueDateStr=2026-11-19, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795080107753, creator=13701087609, updateTime=1795080107753, updator=13701087609, issue=Issue{id=1330225632362999820, tenantId=1146029695717560320, journalId=1319690329412173987, year='2022', volume='43', issue='6', pageStart='643', pageEnd='810', issueExtLink='null', onlineDate='null', pubDate='1654790400000', pubDateStr='2022-06-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795080105152, creator='13701087609', updateTime=1795084738205, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330245065345184449, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225632362999820, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330245065345184450, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225632362999820, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=651, endPage=662, ext={EN=ArticleExt(id=1330225643435962493, articleId=1330225643272384636, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Research progress on clinical application of targeting proprotein convertase subtilisin/kexin type 9 inhibitors, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=

Dyslipidemia, characterized by elevated low density lipoprotein-cholesterol (LDL-C), is an important risk factor for atherosclerotic cardiovascular disease (ASCVD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a class of compounds that inhibit PCSK9 and are a class of new lipid-lowering drugs. It interferes with the recycling of low density lipoprotein receptor (LDLR), thus hindering LDL-C clearance mediated by LDLR, which brings new hope for lipid-lowering therapy. This article reviewed the discovery, structure, regulation and biological functions of PCSK9 targets, focusing on the pharmacodynamics, pharmacokinetics and recent clinical research progress of monoclonal antibodies and small interfering RNA drugs, in order to provide reference for clinical diagnosis and treatment.

, authors=Yali GAO1, Nianxi YU2, Xingyun HOU2, Xia TAO2, *, authorsList=Yali GAO, Nianxi YU, Xingyun HOU, Xia TAO, authorCompany=null, correspAuthors=Xia TAO, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1330225645218541694, articleId=1330225643272384636, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=靶向前蛋白转化酶枯草溶菌素9抑制剂临床应用研究进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

以低密度脂蛋白胆固醇(low density lipoprotein-cholesterol,LDL-C)升高为特点的血脂异常(dyslipidemia)是动脉粥样硬化性心血管疾病(atherosclerotic cardiovascular disease,ASCVD)的1个重要的危险因素,靶向前蛋白转化酶枯草溶菌素9(proprotein convertase subtilisin/kexin type 9,PCSK9)抑制剂是一类抑制PCSK9的化合物,亦为一类降脂新药,可干扰LDL受体的循环利用,从而阻碍其介导的LDL-C的清除,为降脂治疗带来了新的希望。现回顾PCSK9靶点的发现、结构、调节及生物学功能,重点对单克隆抗体和小干扰RNA类药物的药效学、药代动力学及近年来临床研究进展作一综述,旨在为临床诊治提供参考。

, authors=高雅莉1, 余年喜2, 侯幸赟2, 陶霞2, *, authorsList=高雅莉, 余年喜, 侯幸赟, 陶霞, authorCompany=null, correspAuthors=陶霞, authorNote=

# 对本文贡献等同

高雅莉,硕士,主管药师,研究方向:临床药学与糖尿病合理用药。

余年喜,硕士,主管药师,研究方向:临床药学与心血管合理用药。

, correspAuthorsNote=
陶霞,教授,博士,主任药师,研究方向:临床药学与心血管药理学。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=8r46bCq3T8pJPBzM6k5IeQ==, magXml=CcMHGPz7oySjimCJzs4GRA==, pdfUrl=null, pdf=qwEQBhFfVi/CWi/FgXLBCA==, pdfFileSize=1771935, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=cAfn0n2/nQLAGZL+edT76g==, mapNumber=null, fund=null)}, authors=[Author(id=1330225645637972102, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225645721858184, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, authorId=1330225645637972102, language=EN, stringName=Yali GAO, firstName=Yali, middleName=null, lastName=GAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Pharmacy, 2nd Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225645788967049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, authorId=1330225645637972102, language=CN, stringName=高雅莉, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.福建医科大学附属第二医院药学部,福建 泉州 362000, bio={"content":"

高雅莉,硕士,主管药师,研究方向:临床药学与糖尿病合理用药。

"}, bioImg=null, bioContent=

高雅莉,硕士,主管药师,研究方向:临床药学与糖尿病合理用药。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225645453422719, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, xref=1., ext=[AuthorCompanyExt(id=1330225645466005632, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, companyId=1330225645453422719, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, 2nd Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China), AuthorCompanyExt(id=1330225645474394241, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, companyId=1330225645453422719, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.福建医科大学附属第二医院药学部,福建 泉州 362000)])]), Author(id=1330225645847687307, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225645927379086, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, authorId=1330225645847687307, language=EN, stringName=Nianxi YU, firstName=Nianxi, middleName=null, lastName=YU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225646007070863, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, authorId=1330225645847687307, language=CN, stringName=余年喜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.海军军医大学第二附属医院药剂科,上海 2000433, bio={"content":"

余年喜,硕士,主管药师,研究方向:临床药学与心血管合理用药。

"}, bioImg=null, bioContent=

余年喜,硕士,主管药师,研究方向:临床药学与心血管合理用药。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225645541503106, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, xref=2., ext=[AuthorCompanyExt(id=1330225645554086019, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, companyId=1330225645541503106, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China), AuthorCompanyExt(id=1330225645562474628, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, companyId=1330225645541503106, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.海军军医大学第二附属医院药剂科,上海 2000433)])]), Author(id=1330225646086762641, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225646170648723, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, authorId=1330225646086762641, language=EN, stringName=Xingyun HOU, firstName=Xingyun, middleName=null, lastName=HOU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225646254534804, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, authorId=1330225646086762641, language=CN, stringName=侯幸赟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.海军军医大学第二附属医院药剂科,上海 2000433, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225645541503106, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, xref=2., ext=[AuthorCompanyExt(id=1330225645554086019, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, companyId=1330225645541503106, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China), AuthorCompanyExt(id=1330225645562474628, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, companyId=1330225645541503106, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.海军军医大学第二附属医院药剂科,上海 2000433)])]), Author(id=1330225646342615190, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330225646418112665, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, authorId=1330225646342615190, language=EN, stringName=Xia TAO, firstName=Xia, middleName=null, lastName=TAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225646489415834, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, authorId=1330225646342615190, language=CN, stringName=陶霞, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.海军军医大学第二附属医院药剂科,上海 2000433, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225645541503106, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, xref=2., ext=[AuthorCompanyExt(id=1330225645554086019, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, companyId=1330225645541503106, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China), AuthorCompanyExt(id=1330225645562474628, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, companyId=1330225645541503106, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.海军军医大学第二附属医院药剂科,上海 2000433)])])], keywords=[Keyword(id=1330225646602662043, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, language=EN, orderNo=1, keyword=proprotein convertase subtilisin/kexin type 9), Keyword(id=1330225646703325340, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, language=EN, orderNo=2, keyword=low density lipoprotein-cholesterol), Keyword(id=1330225646783017117, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, language=EN, orderNo=3, keyword=atherosclerotic cardiovascular disease), Keyword(id=1330225646841737374, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, language=EN, orderNo=4, keyword=monoclonal antibody), Keyword(id=1330225646913040543, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, language=EN, orderNo=5, keyword=small interfering RNA), Keyword(id=1330225647017898144, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, language=CN, orderNo=1, keyword=前蛋白转化酶枯草溶菌素9), Keyword(id=1330225647085007009, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, language=CN, orderNo=2, keyword=低密度脂蛋白胆固醇), Keyword(id=1330225647143727266, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, language=CN, orderNo=3, keyword=动脉粥样硬化性心血管疾病), Keyword(id=1330225647215030435, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, language=CN, orderNo=4, keyword=单克隆抗体), Keyword(id=1330225647273750692, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, language=CN, orderNo=5, keyword=小干扰RNA)], refs=[Reference(id=1330225647525408934, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2020概要[J]. 中国循环杂志, 2021, 36(6): 521-545., articleTitle=null, refAbstract=null), Reference(id=1330225647613489319, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhao D, Liu J, Wang M, et al. Epidemiology of cardiovascular disease in China: current features and implications[J]. Nat Rev Cardiol, 2019, 16(4): 203-212., articleTitle=null, refAbstract=null), Reference(id=1330225647680598184, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Cholesterol Treatment Trialists'(CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials[J]. Lancet, 2012, 380(9841): 581-590., articleTitle=null, refAbstract=null), Reference(id=1330225647781261481, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis[J]. JAMA, 2016, 316(12): 1289-1297., articleTitle=null, refAbstract=null), Reference(id=1330225647860953258, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk[J]. Eur Heart J, 2020, 41(1): 111-188., articleTitle=null, refAbstract=null), Reference(id=1330225647928062123, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=中国胆固醇教育计划(CCEP)工作委员会, 中国医疗保健国际交流促进会动脉粥样硬化血栓疾病防治分会, 中国老年学和老年医学学会心血管病分会, 等. 中国胆固醇教育计划调脂治疗降低心血管事件专家建议(2019)[J]. 中华内科杂志, 2020, 59(1): 18-22., articleTitle=null, refAbstract=null), Reference(id=1330225649131827374, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=李勇, 赵水平, 叶平, 等. 中国血脂异常门诊患者调脂治疗一级和二级预防达标现状: DYSIS-China亚组分析[J]. 中华心血管病杂志, 2016, 44(8): 665-670., articleTitle=null, refAbstract=null), Reference(id=1330225649228296367, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang M, Deng Q, Wang L, et al. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: a nationally representative survey of 163 641 adults[J]. Int J Cardiol, 2018, 260: 196-203., articleTitle=null, refAbstract=null), Reference(id=1330225649307988144, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Bruckert E, Parhofer KG, Gonzalez-Juanatey JR, et al. Proportion of high-risk/very high-risk patients in Europe with low-density lipoprotein cholesterol at target according to European guidelines: a systematic review[J]. Adv Ther, 2020, 37(5): 1724-1736., articleTitle=null, refAbstract=null), Reference(id=1330225649404457137, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Lansberg P, Lee A, Lee ZV, et al. Nonadherence to statins: individualized intervention strategies outside the pill box[J]. Vasc Health Risk Manag, 2018, 14: 91-102., articleTitle=null, refAbstract=null), Reference(id=1330225649467371698, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012[J]. J Clin Lipidol, 2016, 10(5): 1109-1118., articleTitle=null, refAbstract=null), Reference(id=1330225649530286259, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Jiang J, Zhou YJ, Li JJ, et al. Uncontrolled hyperlipidemia in Chinese patients who experienced acute coronary syndrome: an observational study[J]. Ther Clin Risk Manag, 2018, 14: 2255-2264., articleTitle=null, refAbstract=null), Reference(id=1330225649630949556, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation[J]. Proc Natl Acad Sci USA, 2003, 100(3): 928-933., articleTitle=null, refAbstract=null), Reference(id=1330225649702252725, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia[J]. Nat Genet, 2003, 34(2): 154-156., articleTitle=null, refAbstract=null), Reference(id=1330225649828081846, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Timms KM, Wagner S, Samuels ME, et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree[J]. Hum Genet, 2004, 114(4): 349-353., articleTitle=null, refAbstract=null), Reference(id=1330225649907773623, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia[J]. Clin Genet, 2004, 65(5): 419-422., articleTitle=null, refAbstract=null), Reference(id=1330225649987465400, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Abifadel M, Rabès JP, Boileau C, et al. After the LDL receptor and apolipoprotein B, autosomal dominant hypercholesterolemia reveals its third protagonist: PCSK9[J]. Ann Endocrinol (Paris), 2007, 68(2): 138-146., articleTitle=null, refAbstract=null), Reference(id=1330225650062962873, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease[J]. N Engl J Med, 2006, 354(12): 1264-1272., articleTitle=null, refAbstract=null), Reference(id=1330225650138460346, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Abifadel M, Rabès JP, Devillers M, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9(PCSK9) gene in cholesterol metabolism and disease[J]. Hum Mutat, 2009, 30(4): 520-529., articleTitle=null, refAbstract=null), Reference(id=1330225650218152123, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Piper DE, Jackson S, Liu Q, et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol[J]. Structure, 2007, 15(5): 545-552., articleTitle=null, refAbstract=null), Reference(id=1330225650293649596, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Seidah NG, Awan Z, Chrétien M, et al. PCSK9: a key modulator of cardiovascular health[J]. Circ Res, 2014, 114(6): 1022-1036., articleTitle=null, refAbstract=null), Reference(id=1330225650356564157, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism[J]. J Lipid Res, 2009, 50: S172-S177., articleTitle=null, refAbstract=null), Reference(id=1330225650436255934, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism[J]. Trends Biochem Sci, 2007, 32(2): 71-77., articleTitle=null, refAbstract=null), Reference(id=1330225650520142015, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Jeong HJ, Lee HS, Kim KS, et al. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2[J]. J Lipid Res, 2008, 49(2): 399-409., articleTitle=null, refAbstract=null), Reference(id=1330225650591445184, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver[J]. J Clin Invest, 2002, 109(9): 1125-1131., articleTitle=null, refAbstract=null), Reference(id=1330225650662748353, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Burke AC, Dron JS, Hegele RA, et al. PCSK9: regulation and target for drug development for dyslipidemia[J]. Annu Rev Pharmacol Toxicol, 2017, 57: 223-244., articleTitle=null, refAbstract=null), Reference(id=1330225650734051522, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9[J]. J Lipid Res, 2008, 49(2): 394-398., articleTitle=null, refAbstract=null), Reference(id=1330225650805354691, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Welder G, Zineh I, Pacanowski MA, et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol[J]. J Lipid Res, 2010, 51(9): 2714-2721., articleTitle=null, refAbstract=null), Reference(id=1330225650880852164, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Guo YL, Liu J, Xu RX, et al. Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9[J]. Clin Drug Investig, 2013, 33(12): 877-883., articleTitle=null, refAbstract=null), Reference(id=1330225650947961029, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Li H, Dong B, Park SW, et al. Hepatocyte nuclear factor 1α plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine[J]. J Biol Chem, 2009, 284(42): 28885-28895., articleTitle=null, refAbstract=null), Reference(id=1330225651006681286, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Dong B, Wu M, Li H, et al. Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters[J]. J Lipid Res, 2010, 51(6): 1486-1495., articleTitle=null, refAbstract=null), Reference(id=1330225651090567367, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Shende VR, Wu M, Singh AB, et al. Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice[J]. J Lipid Res, 2015, 56(4): 801-809., articleTitle=null, refAbstract=null), Reference(id=1330225651157676232, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Hussain Y, Ding Q, Connelly PW, et al. G-protein estrogen receptor as a regulator of low-density lipoprotein cholesterol metabolism: cellular and population genetic studies[J]. Arterioscler Thromb Vasc Biol, 2015, 35(1): 213-221., articleTitle=null, refAbstract=null), Reference(id=1330225651216396489, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Poirier S, Mayer G, Poupon V, et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route[J]. J Biol Chem, 2009, 284(42): 28856-28864., articleTitle=null, refAbstract=null), Reference(id=1330225651275116746, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2[J]. J Biol Chem, 2008, 283(4): 2363-2372., articleTitle=null, refAbstract=null), Reference(id=1330225651342225611, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Canuel M, Sun X, Asselin MC, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)[J]. PLoS One, 2013, 8(5): e64145., articleTitle=null, refAbstract=null), Reference(id=1330225651417723084, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=He NY, Li Q, Wu CY, et al. Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives[J]. Acta Pharmacol Sin, 2017, 38(3): 301-311., articleTitle=null, refAbstract=null), Reference(id=1330225651484831949, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Kasichayanula S, Grover A, Emery MG, et al. Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor[J]. Clin Pharmacokinet, 2018, 57(7): 769-779., articleTitle=null, refAbstract=null), Reference(id=1330225651543552206, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates[J]. Proc Natl Acad Sci USA, 2009, 106(24): 9820-9825., articleTitle=null, refAbstract=null), Reference(id=1330225651610661071, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Foltz IN, Karow M, Wasserman SM. Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know[J]. Circulation, 2013, 127(22): 2222-2230., articleTitle=null, refAbstract=null), Reference(id=1330225651698741456, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Ying HY, Wang JC, Zhou BQ. PCSK9 monoclonal antibody: 12 years, from basic research to clinical application[J]. Adv Clin Exp Med, 2019, 9(11): 1255-1260., articleTitle=null, refAbstract=null), Reference(id=1330225651770044625, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Ridker PM, Tardif JC, Amarenco P, et al. Lipid-reduction variability and antidrug-antibody formation with bococizumab[J]. N Engl J Med, 2017, 376(16): 1517-1526., articleTitle=null, refAbstract=null), Reference(id=1330225651828764882, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Lunven C, Paehler T, Poitiers F, et al. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects[J]. Cardiovasc Ther, 2014, 32(6): 297-301., articleTitle=null, refAbstract=null), Reference(id=1330225651883290835, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=姚雅洁, 蔡恒. PCSK9抑制剂Evolocumab与动脉粥样硬化性心血管疾病的研究进展[J]. 心血管病学进展, 2020, 41(12): 1285-1289., articleTitle=null, refAbstract=null), Reference(id=1330225651975565524, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=Li H, Wei Y, Yang Z, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of alirocumab in healthy Chinese subjects: a randomized, double-blind, placebo-controlled, ascending single-dose study[J]. Am J Cardiovasc Drugs, 2020, 20(5): 489-503., articleTitle=null, refAbstract=null), Reference(id=1330225652042674391, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=German CA, Shapiro MD. Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9[J]. BioDrugs, 2020, 34(1): 1-9., articleTitle=null, refAbstract=null), Reference(id=1330225652126560472, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=Khvorova A. Oligonucleotide therapeutics-a new class of cholesterol-lowering drugs[J]. N Engl J Med, 2017, 376(1): 4-7., articleTitle=null, refAbstract=null), Reference(id=1330225652197863641, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9[J]. N Engl J Med, 2017, 376(1): 41-51., articleTitle=null, refAbstract=null), Reference(id=1330225652269166810, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=Lamb YN. Inclisiran: first approval[J]. Drugs, 2021, 81(3): 389-395., articleTitle=null, refAbstract=null), Reference(id=1330225652323692763, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[50], rfOrder=49, authorNames=null, journalName=null, refType=null, unstructuredReference=Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab[J]. J Am Coll Cardiol, 2014, 63(23): 2541-2548., articleTitle=null, refAbstract=null), Reference(id=1330225652386607324, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[51], rfOrder=50, authorNames=null, journalName=null, refType=null, unstructuredReference=Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hyperchole sterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2015, 385(9965): 331-340., articleTitle=null, refAbstract=null), Reference(id=1330225652453716189, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[52], rfOrder=51, authorNames=null, journalName=null, refType=null, unstructuredReference=Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2015, 385(9965): 341-350., articleTitle=null, refAbstract=null), Reference(id=1330225652529213662, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[53], rfOrder=52, authorNames=null, journalName=null, refType=null, unstructuredReference=Raal FJ, Hovingh GK, Blom D, et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study[J]. Lancet Diabetes Endocrinol, 2017, 5(4): 280-290., articleTitle=null, refAbstract=null), Reference(id=1330225652617294047, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[54], rfOrder=53, authorNames=null, journalName=null, refType=null, unstructuredReference=Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial[J]. JAMA, 2014, 311(18): 1870-1882., articleTitle=null, refAbstract=null), Reference(id=1330225652705374432, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[55], rfOrder=54, authorNames=null, journalName=null, refType=null, unstructuredReference=Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med, 2017, 376(18): 1713-1722., articleTitle=null, refAbstract=null), Reference(id=1330225652768288993, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[56], rfOrder=55, authorNames=null, journalName=null, refType=null, unstructuredReference=Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events[J]. N Engl J Med, 2015, 372(16): 1500-1509., articleTitle=null, refAbstract=null), Reference(id=1330225652831203556, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[57], rfOrder=56, authorNames=null, journalName=null, refType=null, unstructuredReference=Koren MJ, Giugliano R, Raal F, et al. Two year analysis of the safety and tolerability of evolocumab: the OSLER-1 study[J]. J Am Coll Cardiol, 2015, 65(10): A1364., articleTitle=null, refAbstract=null), Reference(id=1330225652940255461, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[58], rfOrder=57, authorNames=null, journalName=null, refType=null, unstructuredReference=Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study[J]. JAMA Cardiol, 2017, 2(6): 598-607., articleTitle=null, refAbstract=null), Reference(id=1330225652998975718, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[59], rfOrder=58, authorNames=null, journalName=null, refType=null, unstructuredReference=Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia[J]. J Am Coll Cardiol, 2019, 74(17): 2132-2146., articleTitle=null, refAbstract=null), Reference(id=1330225653078667495, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[60], rfOrder=59, authorNames=null, journalName=null, refType=null, unstructuredReference=Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial[J]. JAMA, 2016, 316(22): 2373-2384., articleTitle=null, refAbstract=null), Reference(id=1330225653141582056, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[61], rfOrder=60, authorNames=null, journalName=null, refType=null, unstructuredReference=Mannarino MR, Sahebkar A, Bianconi V, et al. PCSK9 and neurocognitive function: should it be still an issue after FOURIER and EBBINGHAUS results?[J]. J Clin Lipidol, 2018, 12(5): 1123-1132., articleTitle=null, refAbstract=null), Reference(id=1330225653225468137, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[62], rfOrder=61, authorNames=null, journalName=null, refType=null, unstructuredReference=Roth EM, Taskinen MR, Ginsberg HN, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial[J]. Int J Cardiol, 2014, 176(1): 55-61., articleTitle=null, refAbstract=null), Reference(id=1330225653309354218, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[63], rfOrder=62, authorNames=null, journalName=null, refType=null, unstructuredReference=Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial[J]. J Clin Lipidol, 2015, 9(6): 758-769., articleTitle=null, refAbstract=null), Reference(id=1330225653380657387, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[64], rfOrder=63, authorNames=null, journalName=null, refType=null, unstructuredReference=Bays H, Gaudet D, Weiss R, et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS Ⅰ randomized trial[J]. J Clin Endocrinol Metab, 2015, 100(8): 3140-3148., articleTitle=null, refAbstract=null), Reference(id=1330225653451960556, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[65], rfOrder=64, authorNames=null, journalName=null, refType=null, unstructuredReference=Farnier M, Jones P, Severance R, et al. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS Ⅱ randomized trial[J]. Atherosclerosis, 2016, 244: 138-146., articleTitle=null, refAbstract=null), Reference(id=1330225653527458029, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[66], rfOrder=65, authorNames=null, journalName=null, refType=null, unstructuredReference=Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events[J]. N Engl J Med, 2015, 372(16): 1489-1499., articleTitle=null, refAbstract=null), Reference(id=1330225653598761198, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[67], rfOrder=66, authorNames=null, journalName=null, refType=null, unstructuredReference=Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med, 2018, 379(22): 2097-2107., articleTitle=null, refAbstract=null), Reference(id=1330225653665870063, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[68], rfOrder=67, authorNames=null, journalName=null, refType=null, unstructuredReference=Schwartz G, Szarek M, Li QH, et al. P1226 very low achieved low-density lipoprotein cholesterol level with alirocumab treatment after acute coronary syndrome ODYSSEY OUTCOMES[J]. Eur Heart J, 2019, 40(Suppl 1): P1226., articleTitle=null, refAbstract=null), Reference(id=1330225653774921968, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[69], rfOrder=68, authorNames=null, journalName=null, refType=null, unstructuredReference=Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol[J]. N Engl J Med, 2017, 376(15): 1430-1440., articleTitle=null, refAbstract=null), Reference(id=1330225653863002353, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[70], rfOrder=69, authorNames=null, journalName=null, refType=null, unstructuredReference=Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial[J]. JAMA Cardiol, 2019, 4(11): 1067-1075., articleTitle=null, refAbstract=null), Reference(id=1330225653951082738, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[71], rfOrder=70, authorNames=null, journalName=null, refType=null, unstructuredReference=Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia[J]. N Engl J Med, 2020, 382(16): 1520-1530., articleTitle=null, refAbstract=null), Reference(id=1330225654018191603, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[72], rfOrder=71, authorNames=null, journalName=null, refType=null, unstructuredReference=Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol[J]. N Engl J Med, 2020, 382(16): 1507-1519., articleTitle=null, refAbstract=null), Reference(id=1330225654110466292, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[73], rfOrder=72, authorNames=null, journalName=null, refType=null, unstructuredReference=Wright RS, Ray KK, Raal FJ, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis[J]. J Am Coll Cardiol, 2021, 77(9): 1182-1193., articleTitle=null, refAbstract=null)], funds=[Fund(id=1330225647382802597, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, awardId=null, language=CN, fundingSource=上海市“医苑新星”青年医学人才培养资助计划(青年医学人才类——临床药师项目), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1330225645453422719, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, xref=1., ext=[AuthorCompanyExt(id=1330225645466005632, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, companyId=1330225645453422719, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, 2nd Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China), AuthorCompanyExt(id=1330225645474394241, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, companyId=1330225645453422719, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.福建医科大学附属第二医院药学部,福建 泉州 362000)]), AuthorCompany(id=1330225645541503106, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, xref=2., ext=[AuthorCompanyExt(id=1330225645554086019, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, companyId=1330225645541503106, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China), AuthorCompanyExt(id=1330225645562474628, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, companyId=1330225645541503106, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.海军军医大学第二附属医院药剂科,上海 2000433)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.06.002, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.06.002, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2022.06.002, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2022.06.002, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1654790400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
靶向前蛋白转化酶枯草溶菌素9抑制剂临床应用研究进展
高雅莉 1 , 余年喜 2 , 侯幸赟 2 , 陶霞 2, *
世界临床药物 | 医药专论 2022,43(6): 651-662
收起
收藏切换
世界临床药物 |医药专论 2022 , 43 (6) : 651 -662
靶向前蛋白转化酶枯草溶菌素9抑制剂临床应用研究进展
全屏
[Author(id=1330225645637972102, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225645721858184, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, authorId=1330225645637972102, language=EN, stringName=Yali GAO, firstName=Yali, middleName=null, lastName=GAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Pharmacy, 2nd Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225645788967049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, authorId=1330225645637972102, language=CN, stringName=高雅莉, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.福建医科大学附属第二医院药学部,福建 泉州 362000, bio={"content":"

高雅莉,硕士,主管药师,研究方向:临床药学与糖尿病合理用药。

"}, bioImg=null, bioContent=

高雅莉,硕士,主管药师,研究方向:临床药学与糖尿病合理用药。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225645453422719, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, xref=1., ext=[AuthorCompanyExt(id=1330225645466005632, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, companyId=1330225645453422719, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, 2nd Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China), AuthorCompanyExt(id=1330225645474394241, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, companyId=1330225645453422719, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.福建医科大学附属第二医院药学部,福建 泉州 362000)])]), Author(id=1330225645847687307, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225645927379086, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, authorId=1330225645847687307, language=EN, stringName=Nianxi YU, firstName=Nianxi, middleName=null, lastName=YU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225646007070863, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, authorId=1330225645847687307, language=CN, stringName=余年喜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.海军军医大学第二附属医院药剂科,上海 2000433, bio={"content":"

余年喜,硕士,主管药师,研究方向:临床药学与心血管合理用药。

"}, bioImg=null, bioContent=

余年喜,硕士,主管药师,研究方向:临床药学与心血管合理用药。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225645541503106, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, xref=2., ext=[AuthorCompanyExt(id=1330225645554086019, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, companyId=1330225645541503106, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China), AuthorCompanyExt(id=1330225645562474628, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, companyId=1330225645541503106, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.海军军医大学第二附属医院药剂科,上海 2000433)])]), Author(id=1330225646086762641, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225646170648723, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, authorId=1330225646086762641, language=EN, stringName=Xingyun HOU, firstName=Xingyun, middleName=null, lastName=HOU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225646254534804, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, authorId=1330225646086762641, language=CN, stringName=侯幸赟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.海军军医大学第二附属医院药剂科,上海 2000433, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225645541503106, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, xref=2., ext=[AuthorCompanyExt(id=1330225645554086019, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, companyId=1330225645541503106, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China), AuthorCompanyExt(id=1330225645562474628, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, companyId=1330225645541503106, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.海军军医大学第二附属医院药剂科,上海 2000433)])]), Author(id=1330225646342615190, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330225646418112665, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, authorId=1330225646342615190, language=EN, stringName=Xia TAO, firstName=Xia, middleName=null, lastName=TAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225646489415834, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, authorId=1330225646342615190, language=CN, stringName=陶霞, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.海军军医大学第二附属医院药剂科,上海 2000433, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225645541503106, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, xref=2., ext=[AuthorCompanyExt(id=1330225645554086019, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, companyId=1330225645541503106, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China), AuthorCompanyExt(id=1330225645562474628, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225643272384636, companyId=1330225645541503106, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.海军军医大学第二附属医院药剂科,上海 2000433)])])]
高雅莉1, 余年喜2, 侯幸赟2, 陶霞2, *
作者信息
  • 1.福建医科大学附属第二医院药学部,福建 泉州 362000
  • 2.海军军医大学第二附属医院药剂科,上海 2000433
通讯作者:
陶霞,教授,博士,主任药师,研究方向:临床药学与心血管药理学。
作者简介:

# 对本文贡献等同

高雅莉,硕士,主管药师,研究方向:临床药学与糖尿病合理用药。

余年喜,硕士,主管药师,研究方向:临床药学与心血管合理用药。

Research progress on clinical application of targeting proprotein convertase subtilisin/kexin type 9 inhibitors
Yali GAO1, Nianxi YU2, Xingyun HOU2, Xia TAO2, *
Affiliations
  • 1.Department of Pharmacy, 2nd Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China
  • 2.Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200433, China
出版时间: 2022-06-10 doi: 10.13683/j.wph.2022.06.002
文章导航
收藏切换

以低密度脂蛋白胆固醇(low density lipoprotein-cholesterol,LDL-C)升高为特点的血脂异常(dyslipidemia)是动脉粥样硬化性心血管疾病(atherosclerotic cardiovascular disease,ASCVD)的1个重要的危险因素,靶向前蛋白转化酶枯草溶菌素9(proprotein convertase subtilisin/kexin type 9,PCSK9)抑制剂是一类抑制PCSK9的化合物,亦为一类降脂新药,可干扰LDL受体的循环利用,从而阻碍其介导的LDL-C的清除,为降脂治疗带来了新的希望。现回顾PCSK9靶点的发现、结构、调节及生物学功能,重点对单克隆抗体和小干扰RNA类药物的药效学、药代动力学及近年来临床研究进展作一综述,旨在为临床诊治提供参考。

前蛋白转化酶枯草溶菌素9  /  低密度脂蛋白胆固醇  /  动脉粥样硬化性心血管疾病  /  单克隆抗体  /  小干扰RNA

Dyslipidemia, characterized by elevated low density lipoprotein-cholesterol (LDL-C), is an important risk factor for atherosclerotic cardiovascular disease (ASCVD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a class of compounds that inhibit PCSK9 and are a class of new lipid-lowering drugs. It interferes with the recycling of low density lipoprotein receptor (LDLR), thus hindering LDL-C clearance mediated by LDLR, which brings new hope for lipid-lowering therapy. This article reviewed the discovery, structure, regulation and biological functions of PCSK9 targets, focusing on the pharmacodynamics, pharmacokinetics and recent clinical research progress of monoclonal antibodies and small interfering RNA drugs, in order to provide reference for clinical diagnosis and treatment.

proprotein convertase subtilisin/kexin type 9  /  low density lipoprotein-cholesterol  /  atherosclerotic cardiovascular disease  /  monoclonal antibody  /  small interfering RNA
高雅莉, 余年喜, 侯幸赟, 陶霞. 靶向前蛋白转化酶枯草溶菌素9抑制剂临床应用研究进展. 世界临床药物, 2022 , 43 (6) : 651 -662 . DOI: 10.13683/j.wph.2022.06.002
Yali GAO, Nianxi YU, Xingyun HOU, Xia TAO. Research progress on clinical application of targeting proprotein convertase subtilisin/kexin type 9 inhibitors[J]. World Clinical Drug, 2022 , 43 (6) : 651 -662 . DOI: 10.13683/j.wph.2022.06.002
  • 上海市“医苑新星”青年医学人才培养资助计划(青年医学人才类——临床药师项目)
参考文献 引证文献
排序方式:
[1]
中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2020概要[J]. 中国循环杂志, 2021, 36(6): 521-545.
[2]
Zhao D, Liu J, Wang M, et al. Epidemiology of cardiovascular disease in China: current features and implications[J]. Nat Rev Cardiol, 2019, 16(4): 203-212.
[3]
Cholesterol Treatment Trialists'(CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials[J]. Lancet, 2012, 380(9841): 581-590.
[4]
Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis[J]. JAMA, 2016, 316(12): 1289-1297.
[5]
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk[J]. Eur Heart J, 2020, 41(1): 111-188.
[6]
中国胆固醇教育计划(CCEP)工作委员会, 中国医疗保健国际交流促进会动脉粥样硬化血栓疾病防治分会, 中国老年学和老年医学学会心血管病分会, 等. 中国胆固醇教育计划调脂治疗降低心血管事件专家建议(2019)[J]. 中华内科杂志, 2020, 59(1): 18-22.
[7]
李勇, 赵水平, 叶平, 等. 中国血脂异常门诊患者调脂治疗一级和二级预防达标现状: DYSIS-China亚组分析[J]. 中华心血管病杂志, 2016, 44(8): 665-670.
[8]
Zhang M, Deng Q, Wang L, et al. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: a nationally representative survey of 163 641 adults[J]. Int J Cardiol, 2018, 260: 196-203.
[9]
Bruckert E, Parhofer KG, Gonzalez-Juanatey JR, et al. Proportion of high-risk/very high-risk patients in Europe with low-density lipoprotein cholesterol at target according to European guidelines: a systematic review[J]. Adv Ther, 2020, 37(5): 1724-1736.
[10]
Lansberg P, Lee A, Lee ZV, et al. Nonadherence to statins: individualized intervention strategies outside the pill box[J]. Vasc Health Risk Manag, 2018, 14: 91-102.
[11]
Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012[J]. J Clin Lipidol, 2016, 10(5): 1109-1118.
[12]
Jiang J, Zhou YJ, Li JJ, et al. Uncontrolled hyperlipidemia in Chinese patients who experienced acute coronary syndrome: an observational study[J]. Ther Clin Risk Manag, 2018, 14: 2255-2264.
[13]
Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation[J]. Proc Natl Acad Sci USA, 2003, 100(3): 928-933.
[14]
Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia[J]. Nat Genet, 2003, 34(2): 154-156.
[15]
Timms KM, Wagner S, Samuels ME, et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree[J]. Hum Genet, 2004, 114(4): 349-353.
[16]
Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia[J]. Clin Genet, 2004, 65(5): 419-422.
[17]
Abifadel M, Rabès JP, Boileau C, et al. After the LDL receptor and apolipoprotein B, autosomal dominant hypercholesterolemia reveals its third protagonist: PCSK9[J]. Ann Endocrinol (Paris), 2007, 68(2): 138-146.
[18]
Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease[J]. N Engl J Med, 2006, 354(12): 1264-1272.
[19]
Abifadel M, Rabès JP, Devillers M, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9(PCSK9) gene in cholesterol metabolism and disease[J]. Hum Mutat, 2009, 30(4): 520-529.
[20]
Piper DE, Jackson S, Liu Q, et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol[J]. Structure, 2007, 15(5): 545-552.
[21]
Seidah NG, Awan Z, Chrétien M, et al. PCSK9: a key modulator of cardiovascular health[J]. Circ Res, 2014, 114(6): 1022-1036.
[22]
Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism[J]. J Lipid Res, 2009, 50: S172-S177.
[23]
Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism[J]. Trends Biochem Sci, 2007, 32(2): 71-77.
[24]
Jeong HJ, Lee HS, Kim KS, et al. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2[J]. J Lipid Res, 2008, 49(2): 399-409.
[25]
Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver[J]. J Clin Invest, 2002, 109(9): 1125-1131.
[26]
Burke AC, Dron JS, Hegele RA, et al. PCSK9: regulation and target for drug development for dyslipidemia[J]. Annu Rev Pharmacol Toxicol, 2017, 57: 223-244.
[27]
Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9[J]. J Lipid Res, 2008, 49(2): 394-398.
[28]
Welder G, Zineh I, Pacanowski MA, et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol[J]. J Lipid Res, 2010, 51(9): 2714-2721.
[29]
Guo YL, Liu J, Xu RX, et al. Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9[J]. Clin Drug Investig, 2013, 33(12): 877-883.
[30]
Li H, Dong B, Park SW, et al. Hepatocyte nuclear factor 1α plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine[J]. J Biol Chem, 2009, 284(42): 28885-28895.
[31]
Dong B, Wu M, Li H, et al. Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters[J]. J Lipid Res, 2010, 51(6): 1486-1495.
[32]
Shende VR, Wu M, Singh AB, et al. Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice[J]. J Lipid Res, 2015, 56(4): 801-809.
[33]
Hussain Y, Ding Q, Connelly PW, et al. G-protein estrogen receptor as a regulator of low-density lipoprotein cholesterol metabolism: cellular and population genetic studies[J]. Arterioscler Thromb Vasc Biol, 2015, 35(1): 213-221.
[34]
Poirier S, Mayer G, Poupon V, et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route[J]. J Biol Chem, 2009, 284(42): 28856-28864.
[35]
Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2[J]. J Biol Chem, 2008, 283(4): 2363-2372.
[36]
Canuel M, Sun X, Asselin MC, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)[J]. PLoS One, 2013, 8(5): e64145.
[37]
He NY, Li Q, Wu CY, et al. Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives[J]. Acta Pharmacol Sin, 2017, 38(3): 301-311.
[38]
Kasichayanula S, Grover A, Emery MG, et al. Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor[J]. Clin Pharmacokinet, 2018, 57(7): 769-779.
[39]
Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates[J]. Proc Natl Acad Sci USA, 2009, 106(24): 9820-9825.
[40]
Foltz IN, Karow M, Wasserman SM. Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know[J]. Circulation, 2013, 127(22): 2222-2230.
[41]
Ying HY, Wang JC, Zhou BQ. PCSK9 monoclonal antibody: 12 years, from basic research to clinical application[J]. Adv Clin Exp Med, 2019, 9(11): 1255-1260.
[42]
Ridker PM, Tardif JC, Amarenco P, et al. Lipid-reduction variability and antidrug-antibody formation with bococizumab[J]. N Engl J Med, 2017, 376(16): 1517-1526.
[43]
Lunven C, Paehler T, Poitiers F, et al. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects[J]. Cardiovasc Ther, 2014, 32(6): 297-301.
[44]
姚雅洁, 蔡恒. PCSK9抑制剂Evolocumab与动脉粥样硬化性心血管疾病的研究进展[J]. 心血管病学进展, 2020, 41(12): 1285-1289.
[45]
Li H, Wei Y, Yang Z, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of alirocumab in healthy Chinese subjects: a randomized, double-blind, placebo-controlled, ascending single-dose study[J]. Am J Cardiovasc Drugs, 2020, 20(5): 489-503.
[46]
German CA, Shapiro MD. Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9[J]. BioDrugs, 2020, 34(1): 1-9.
[47]
Khvorova A. Oligonucleotide therapeutics-a new class of cholesterol-lowering drugs[J]. N Engl J Med, 2017, 376(1): 4-7.
[48]
Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9[J]. N Engl J Med, 2017, 376(1): 41-51.
[49]
Lamb YN. Inclisiran: first approval[J]. Drugs, 2021, 81(3): 389-395.
[50]
Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab[J]. J Am Coll Cardiol, 2014, 63(23): 2541-2548.
[51]
Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hyperchole sterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2015, 385(9965): 331-340.
[52]
Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2015, 385(9965): 341-350.
[53]
Raal FJ, Hovingh GK, Blom D, et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study[J]. Lancet Diabetes Endocrinol, 2017, 5(4): 280-290.
[54]
Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial[J]. JAMA, 2014, 311(18): 1870-1882.
[55]
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med, 2017, 376(18): 1713-1722.
[56]
Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events[J]. N Engl J Med, 2015, 372(16): 1500-1509.
[57]
Koren MJ, Giugliano R, Raal F, et al. Two year analysis of the safety and tolerability of evolocumab: the OSLER-1 study[J]. J Am Coll Cardiol, 2015, 65(10): A1364.
[58]
Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study[J]. JAMA Cardiol, 2017, 2(6): 598-607.
[59]
Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia[J]. J Am Coll Cardiol, 2019, 74(17): 2132-2146.
[60]
Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial[J]. JAMA, 2016, 316(22): 2373-2384.
[61]
Mannarino MR, Sahebkar A, Bianconi V, et al. PCSK9 and neurocognitive function: should it be still an issue after FOURIER and EBBINGHAUS results?[J]. J Clin Lipidol, 2018, 12(5): 1123-1132.
[62]
Roth EM, Taskinen MR, Ginsberg HN, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial[J]. Int J Cardiol, 2014, 176(1): 55-61.
[63]
Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial[J]. J Clin Lipidol, 2015, 9(6): 758-769.
[64]
Bays H, Gaudet D, Weiss R, et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS Ⅰ randomized trial[J]. J Clin Endocrinol Metab, 2015, 100(8): 3140-3148.
[65]
Farnier M, Jones P, Severance R, et al. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS Ⅱ randomized trial[J]. Atherosclerosis, 2016, 244: 138-146.
[66]
Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events[J]. N Engl J Med, 2015, 372(16): 1489-1499.
[67]
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med, 2018, 379(22): 2097-2107.
[68]
Schwartz G, Szarek M, Li QH, et al. P1226 very low achieved low-density lipoprotein cholesterol level with alirocumab treatment after acute coronary syndrome ODYSSEY OUTCOMES[J]. Eur Heart J, 2019, 40(Suppl 1): P1226.
[69]
Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol[J]. N Engl J Med, 2017, 376(15): 1430-1440.
[70]
Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial[J]. JAMA Cardiol, 2019, 4(11): 1067-1075.
[71]
Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia[J]. N Engl J Med, 2020, 382(16): 1520-1530.
[72]
Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol[J]. N Engl J Med, 2020, 382(16): 1507-1519.
[73]
Wright RS, Ray KK, Raal FJ, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis[J]. J Am Coll Cardiol, 2021, 77(9): 1182-1193.
2022年第43卷第6期
9
2
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2022.06.002
  • 接收时间:2021-12-01
  • 首发时间:2026-11-19
  • 出版时间:2022-06-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2021-12-01
  • 修回日期:2022-04-12
基金
上海市“医苑新星”青年医学人才培养资助计划(青年医学人才类——临床药师项目)
作者信息
    1.福建医科大学附属第二医院药学部,福建 泉州 362000
    2.海军军医大学第二附属医院药剂科,上海 2000433

通讯作者:

陶霞,教授,博士,主任药师,研究方向:临床药学与心血管药理学。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.06.002
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏